

**The Cochrane Collaboration**

(A company limited by guarantee)

**Report and Financial Statements**

**For the year ended 31 March 2013**

Company Number 3044323

Charity Number 1045921

# THE COCHRANE COLLABORATION

31 MARCH 2013

## INDEX

	Page
Trustees' Report	1-7
Independent Auditor's Report	8
Statement of Financial Activities	9
Consolidated Statement of Financial Activities	10
Charity and Consolidated Balance Sheet	11
Notes to the Financial Statements	12-22

**THE COCHRANE COLLABORATION  
TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013**

The Trustees of The Cochrane Collaboration, who are also directors for the purpose of company law, present their report and financial statements for the year ended 31 March 2013.

**Reference and Administration**

Charity name: The Cochrane Collaboration

Registered and  
Correspondence Address: Summertown Pavilion  
18-24 Middle Way  
Oxford  
OX2 7LG  
UK

**Advisors**

Auditors: Mazars LLP  
Chartered Accountants and Statutory Auditors  
The Pinnacle  
160 Midsummer Boulevard  
Milton Keynes  
MK9 1FF  
UK

Bankers: National Westminster Bank PLC  
Oxford North Branch  
249 Banbury Road  
Summertown  
Oxford  
OX2 7HR  
UK

Legal advisers: Manches LLP  
Solicitors  
9400 Garsington Road  
Oxford Business Park  
Oxford  
OX4 2HN  
UK

# THE COCHRANE COLLABORATION

## TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

### Trustees

The governing body of The Cochrane Collaboration is known as the Cochrane Collaboration Steering Group (CCSG). The following trustees, who are also the directors for the purposes of company law, have held office on the CCSG during the year and to the date of signing these financial statements:

Mrs S Bell-Syer  
Dr R Churchill  
Prof J Craig (Co-Chair; reappointed for second term)  
Prof J Grimshaw (Co-Chair)  
Ms GY Higgins (resigned in October 2012)  
Prof JPT Higgins  
Dr S Hill (resigned in October 2012)  
Dr S McDonald  
Ms M Nasser  
Ms ME Schaafsma  
Ms D Thomson  
Mrs E Whamond  
Ms M Zhang  
Dr M Davoli (appointed in October 2012)  
Ms M Fiander (appointed in October 2012)

### Senior Staff

The senior staff of the charity during the year comprised Mr M Wilson, Chief Executive Officer, Dr D Tovey, Editor in Chief, *The Cochrane Library*, and Ms VM Hetherington, Company Secretary and Administrator.

### Narrative Report

#### 1. Structure, Governance and Management

##### Nature of Governing Document

The governing documents of The Cochrane Collaboration are the Memorandum and Articles of Association, as amended on 3 October 2004.

##### Trustee Appointment

Trustees serve as Steering Group members for a three-year period, and may be re-elected for a second consecutive term. After a three-year break, they may be elected again when an appropriate vacancy occurs. Trustees are elected by the official members of the Collaboration (which are the individual operating units, or Cochrane 'Entities') to specific posts representative of their membership group.

##### Organisational Structure

In 2012-13 the Charity was organised as follows:

An elected Steering Group comprising 13 elected Trustees governed The Cochrane Collaboration on behalf of its Members.

Cochrane Entities across the world contributed to the activities of the Collaboration:

- 53 subject-based Cochrane Systematic Review Groups facilitated the preparation, by volunteer contributors, of Cochrane Systematic Reviews;
- 14 Cochrane Centres and 18 regional Branches in Europe, the Americas, Africa, Asia and Australasia provided a regional focus for the Collaboration's activities;
- 13 thematic Fields and Networks represented cross-cutting health issues and carried out knowledge translation and advocacy activity;
- 16 Methods Groups provided support in methods for research evidence synthesis.

Each Cochrane Entity had a devolved management team appropriate to its function. For Cochrane Systematic Review Groups, for instance, this normally consisted of a Co-ordinating Editor (commonly a senior healthcare professional such as a Professor or Senior Consultant with extensive knowledge of the healthcare area concerned), a Managing Editor, a Trials Search Co-ordinator, and administrative support. These teams supported 'Cochrane Systematic Review production teams', consisting of authors and editors; with input provided by statisticians, other methodologists, healthcare consumers and others.

## THE COCHRANE COLLABORATION

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

The Cochrane Collaboration's Interim Chief Executive Officer, Paul Farenden (from April 2012 to 11 November 2012), then the newly appointed CEO Mark Wilson (from 12 November 2012), had overarching responsibility for the management of the Collaboration, including its Central Executive (the staff employed by the Charity or through Charity funding). This included direct management of the Operations Unit, based in Oxford, UK, which co-ordinated the business, financial and organisational functions of the organisation.

The Editor in Chief of *The Cochrane Library*, Dr David Tovey, led the Editorial Unit, based in London, UK, and was responsible for developing, implementing, and directing the editorial policies and vision of *The Cochrane Library* in relation to the vision and objectives of the Collaboration; improving the quality in the editing process and product with respect to scientific content; providing a strong and visionary lead for conceptualising and developing new products derived from Cochrane Systematic Reviews in partnership with the Chief Executive Officer; and for applying ethical and scientific standards consistent with the goals of the Collaboration.

The Cochrane Web Development Team, based in Freiburg, Germany, managed the Collaboration's online presence; and the Cochrane Information Management Systems (IMS) Team, based in Copenhagen, Denmark, was responsible for developing and maintaining RevMan, the Collaboration's systematic review management software; and Archie, the online repository for the Collaboration's documents and contact details.

#### Risk Management

The board of Trustees has considered the principal risks to which The Cochrane Collaboration is exposed. It uses a risk management matrix to set out and evaluate the major risks, their likely impact, and the steps taken to mitigate risk, and further action that could be taken. The key risks in 2012-13 were considered to be:

- The catastrophic loss of core publishing income, which funds the Collaboration's core activities;
- The risk of publishing a Cochrane Systematic Review containing significant errors that might affect public safety.

Contingency plans have been developed to manage these events.

#### Induction and Training of Trustees

The Operations Unit inducts new Trustees into their responsibilities as members of the Board by sending them an extensive collection of materials in advance of their joining the Board. These materials include such documents as the Memorandum and Articles of Association, the most recently-approved Trustees Report and Financial Statements, descriptions of the Steering Group's sub- and advisory committees (some of which they will join), an organisational chart, minutes of several previous Trustees' meetings, the Charity's interim strategic plan and key policies, and the latest risk assessment tables.

## 2. Objectives and Activities

#### Legal Objects

The legal objects of the Charity, as defined in the Memorandum and Articles of Association, are:

"The protection and preservation of public health through the preparation, maintenance and dissemination of systematic reviews of the effects of health care, for the public benefit."

#### Aims of the Charity

The aims of the Charity are as follows:

The Cochrane Collaboration is an international organisation that aims to help people make well-informed decisions about healthcare by preparing, maintaining and promoting the accessibility of systematic reviews of the effects of healthcare interventions.

The Cochrane Collaboration's vision is that healthcare decision-making throughout the world will be informed by high quality, timely research evidence. The Cochrane Collaboration will play a pivotal role in the production and dissemination of this evidence across all areas of health care.

#### Contribution of Volunteers

The Charity makes extensive use of volunteers, with more than 31,000 people from 120 countries currently contributing their time in some way. Amongst their many contributions, volunteers were involved in the following activities:

- Preparation of the Collaboration's outputs as members of 'Cochrane Systematic Review production teams';
- Developing the knowledge base and tools for facilitating preparation of the Collaboration's outputs;
- Dissemination of the Collaboration's principles and outputs through conference presentations, symposia, scientific papers, and related activities;
- Engagement of healthcare consumers in the Collaboration's activities.

It is impossible to calculate the monetary value of volunteers' contributions, but if the work they perform were to be done at commercial rates their contributions would cost tens of millions of pounds per year.

# THE COCHRANE COLLABORATION

## TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

### Objectives for the year

The objectives for the year 2012-13 were:

1. To ensure high quality Cochrane Systematic Reviews are available across a broad range of healthcare topics;
2. To promote access to Cochrane Systematic Reviews and the other products of The Cochrane Collaboration;
3. To ensure an efficient, transparent organisational structure and management system for The Cochrane Collaboration;
4. To achieve sustainability of The Cochrane Collaboration.

### Significant Activities

The Charity undertook the following major activities in the year:

- It published 678 new protocols for forthcoming Cochrane Systematic Reviews, 438 new Cochrane Systematic Reviews and 541 updated Cochrane Systematic Reviews (new citation versions) in *The Cochrane Library*;
- It renewed and re-defined its publishing partnership with John Wiley & Sons, Ltd., to publish *The Cochrane Library* from February 2013 for a further six years, to the end of 2018. Under the new publishing agreement, all Cochrane Systematic Reviews and updates published from February 2013 will become available on an open access basis 12 months after publication in the Cochrane Database of Systematic Reviews, and in PubMed Central or various country-specific PubMed databases. Additionally, authors and funders will have the option to fund individual articles, or groups of articles, to be open access immediately upon publication. Authors from many low- and middle-income countries will be eligible to have their publication fees waived. More than half the world's population already has 'one-click' access to Cochrane content through licenses or free access through the low- and middle- income countries programme;
- It appointed a new Chief Executive Officer, Mark Wilson, in November 2012. He analysed the future executive needs of the organisation and in the first quarter of 2013 the Steering Group approved plans to consolidate the individual teams of the Central Executive (Operations Unit, Editorial Unit, Web Team and IMS Team) into one integrated structure, which would also be expanded in order to support the Collaboration's governance, entities and contributors better; and help to deliver the Charity's future objectives;
- A review and analysis of the Collaboration's strategic framework was conducted in preparation for the revision of the organisation's strategic plan, to be ratified by the Collaboration's membership at the Annual General Meeting in September 2013;
- Dr David Tovey, the Editor in Chief, continued to oversee the preparation and maintenance of Cochrane Systematic Reviews and related products, and ensure their continuing high quality;
- The Collaboration held its annual conference - the 'Colloquium' - in Auckland, New Zealand, in September 2012. The Colloquium was attended by 573 delegates from 43 countries.

## 3. Achievements and Performance

### Review of Activities in the year

Highlights of The Cochrane Collaboration's achievements in 2012-13 include (see also *Significant Activities*, above):

*To ensure high quality Cochrane Systematic Reviews are available across a broad range of healthcare topics*

- Delivery of improvements as part of the *Cochrane Content Publication and Delivery Programme*, a multi-year programme led by the Editorial Unit to enhance *The Cochrane Library* user experience; content creation and quality; dissemination and impact;
- Prioritisation of updating Cochrane Systematic Reviews to ensure that they remain relevant and accurate, as highlighted by the new versus updated review figures;
- Development of implementation mechanisms for the *Methodological standards for the conduct of new Cochrane Intervention Reviews* (the MECIR programme);
- Standardisation of minimum competencies for review author teams;
- Continued funding of six projects addressing methods priorities through the Methods Innovation Fund, part of the *Cochrane Methods* initiative;
- Continued development of the information management systems that support the preparation of Cochrane Systematic Reviews.

*To promote access to Cochrane Systematic Reviews and the other products of the Cochrane Collaboration*

- Delivery of product and accessibility improvements as part of the *Cochrane Content Publication and Delivery Programme* (see above);
- Cochrane's *summaries.cochrane.org*, a portal aimed at consumers and patients providing plain language summaries and abstracts of Cochrane Systematic Reviews, was expanded with important new features including a built-in glossary that automatically highlights and defines technical terms; search terms which are mapped to a drug name database providing users with the generic and brand names for the drug term for which they are searching; and searching made possible in Spanish, French and German;
- Continued progress on the development and implementation of a strategy to translate and signpost non-English language content, co-ordinated by the Translations Working Group and Editorial Unit;

## THE COCHRANE COLLABORATION

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

- Continued work with the World Health Organization, with whom we are in official relations, including sending delegates to the annual World Health Assembly in Geneva and contributing to the WHO Guidelines Review Committee.

*To ensure an efficient, transparent organisational structure and management system for the Cochrane Collaboration*

- Continued activities aimed at supporting new contributors and sustaining the skills and commitment of current contributors through the implementation of the *Cochrane Training* initiative;
- Continued progress in improving the organisation's monitoring and management functions via the Central Executive and Entity Executives;
- Consolidation of the Steering Group and entity executives' reporting structure;
- Continuation of the work to revise the Collaboration's Colloquium Sponsorship Policy;
- Continuation of regular Steering Group teleconferences in addition to bi-annual face-to-face meetings to improve the efficiency of the Group, which sets policy for the organisation as a whole;
- Acceptance of the invitation of the Central American and Spanish Caribbean (CASP) branch of the Iberoamerican Cochrane Centre and the Panamá Cochrane Collaborative Unit to host the annual mid-year meetings in Panamá in March/April 2014;
- Acceptance of the invitation of the South Asian Cochrane Centre to host the annual Cochrane Colloquium in Hyderabad, India, in September 2014 and the 2015 Colloquium in Vienna, Austria.

*To achieve the sustainability of the Cochrane Collaboration*

- Continued progress towards the establishment of the *Cochrane initiative to build global capacity in systematic reviews*, a formal training and mentoring programme to support first-time authors of Cochrane Systematic Reviews, wherever they are in the world;
- Provision of additional funding for and oversight of the Charity's second trading company, *Cochrane Innovations*, which aims to provide an avenue for the marketing of new Cochrane products – and thereby diversifying the funding base - without compromising our principal obligations as a Charity;
- Continuation of preparations to celebrate the 20<sup>th</sup> anniversary of the Collaboration's existence throughout 2013.

#### **Fundraising Performance**

The Cochrane Collaboration's core income is derived principally from publication royalties from its main output, *The Cochrane Library*, published on its behalf by John Wiley & Sons, Ltd. During 2012-13 the income from this source increased, compared to 2011-12, again exceeding expectations based on global economic conditions.

#### **4. Financial Review**

##### **Reserves Policy**

The aim of the Charity's Reserves Policy is to accumulate sufficient funds to enable us to achieve our long-term strategic aims, and then to allocate these funds to projects of Collaboration-wide impact over single- or multi-year projects as required. A review of potential future project needs which will require substantial 'one-off' funding from the Charity's reserves will be conducted in 2013-14 following completion of the Collaboration's *Strategy to 2020*. Allowing for these future new investments, it is the Trustees' judgement that there are sufficient resources to allow us to achieve our strategic aims over the next few years, whilst still being able to react flexibly to and take advantage of opportunities and challenges as they arise.

It is also the policy of the Trustees to have a contingency plan for maintaining the Collaboration's basic functions for twelve months in the event of the loss of core income from publishing. The resources necessary to enact the contingency plan are reviewed on an annual basis.

##### **Discretionary Fund**

A Fund to the value of £15,000 per year was designed to facilitate small projects of general benefit to a majority of the Collaboration's Entities. Three projects received funding this year:

- A contribution towards the costs of the Cochrane Indaba in Cape Town, South Africa, in May 2013;
- Funding for face-to-face meetings of the RevMan Advisory Committee in Auckland, New Zealand, in September 2012, and London, UK, in March 2013;
- The development of a consumer-friendly management interface to complement a mobile 'app' to simplify screening as part of a systematic review.

Other designated funds are set out in the notes to these financial statements.

##### **Funds in Deficit**

There were no funds in deficit in the year.

## THE COCHRANE COLLABORATION

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

#### Investment Policy

The Cochrane Collaboration has no investments other than deposit accounts. The Charity's current policy regarding investment is to put all surplus income into interest-bearing savings accounts. The funds for items of expenditure need to be readily available, in keeping with the ten-day notice periods on these accounts.

#### Principal Funding Sources

##### *Funding model*

Core income referred to in this report comes from publishing income, as described above ('Fundraising Performance'). Core funds used to fund the Central Executive are also directed at programmes considered of key strategic importance, including *Cochrane Training* and *Cochrane Methods*.

Funding to support Cochrane Systematic Review preparation and related activities comes principally from national and trans-national government sources (typically from health and related ministries); and national and international charitable bodies. Some Entities also raise funds through conference hosting and training activities.

The Entities who contribute towards the work of the Collaboration are based within other organisations - such as universities and hospitals - which provide direct or indirect funding to support them. Entities are responsible for their own funding and for sourcing funding to support Cochrane Systematic Review preparation and related activities.

##### *Policy on commercial sponsorship*

The Collaboration maintains a clear barrier between the production of Cochrane Systematic Reviews and any funding from commercial sources with financial interests in the conclusions of the reviews. Thus, sponsorship of a Cochrane Systematic Review by any commercial source or sources is prohibited (A 'commercial source' is any for-profit manufacturer or provider of health care, or any other for-profit source with a real or potential vested interest in the findings of a specific review.). A Foundation Fund was established in 2005 to accept donations from conflicted sources. Whilst government departments, not-for-profit medical insurance companies and health management organisations may find the conclusions of Cochrane Systematic Reviews carry financial consequences for them, these are not included in the definition of commercial source. Also not included are for-profit companies that do not have real or potential vested interests in Cochrane Systematic Reviews.

Other sponsorship of The Cochrane Collaboration's activities is allowed, but a sponsor should not be allowed to delay or prevent publication of a Cochrane Systematic Review, or to interfere with the independence of the authors of reviews in regard to the conduct of their reviews, and the protocol for a Cochrane Systematic Review should specifically mention that a sponsor cannot prevent certain outcome measures being assessed in the review.

The Collaboration's policy surrounding commercial sponsorship of Cochrane Colloquia was revised in 2012, following a review by the Colloquium Policy Advisory Committee and approval by the Steering Group. Previously, commercial sponsorship had been allowed under limited circumstances. The revised policy prohibits any sponsorship from commercial sources (as defined above) thus bringing the policy for Colloquia in line with the Collaboration's overall policy on commercial sponsorship.

## 5. Future Plans

The Charity's major objectives for 2013-14 are:

- To finalise and begin implementation of the Collaboration's new strategic plan, *Cochrane Strategy to 2020*, which will provide a vision, framework and guide for all areas of its work in the next six years;
- To establish a set of one or two-year targets linked to the Goals and Objectives in this strategic plan, which will be regularly reviewed and annually revised in order to ensure adequate progress is being made in delivering them;
- To complete the development of the Central Executive (made up of the Operations Unit, Editorial Unit, Web Development Team and IMS Team) in order to support Collaboration Entities and contributors better and help deliver our strategic goals;
- To continue to produce high-quality systematic reviews; and work more closely with the Collaboration's publishing partner, John Wiley & Sons, Ltd., to ensure these reach the widest possible audience;
- To increase the speed of development of new products and services based on *The Cochrane Library* in order to diversify the organisation's funding base; and to work more closely with the Collaboration's long-time infrastructural funders and supporters.

#### Public Benefit Statement

This public benefit statement has been drawn up in accordance with the Charity Commission's January 2008 guidance on public benefit:

To deliver high quality healthcare services, medical and allied health professionals depend on high-quality information about the effects and effectiveness of the health interventions available to meet population or individual health and healthcare needs. Health consumers, including patients, need to be able to make valid choices between the various options open to them. Huge amounts of information are available; hundreds of thousands of scientific articles are published every year. Nobody can assimilate this mass of information.



# THE COCHRANE COLLABORATION

## TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2013 (continued)

The primary public benefit provided by The Cochrane Collaboration, therefore, relates to the advancement of health by assimilating, on behalf of the world's population, the results of primary research relating to individual treatments, and then presenting these results in a single scientific paper (a 'Cochrane Systematic Review'), formulated to be accessible to both healthcare consumer and practitioner.

The secondary public benefit relates to the advancement of education. Producing hundreds of Cochrane Systematic Reviews each year requires the assistance of 31,000 contributors, principally health professionals, patients and their representatives, and academics. These contributors need to be trained in the advanced techniques necessary for the work, and so international educational initiatives are a key part of the Collaboration's activities.

The third public benefit relates to the Collaboration's role in informing and improving the agenda for primary research by shaping it around the decisions that people are taking in health; identifying uncertainties, missing or poor evidence; and improving health research methodologies.

### Statement of Trustees' responsibilities

Company law requires the trustees to prepare the financial statements for each financial year, which give a true and fair view of the state of affairs of the company and of the surplus or deficit of the company for that period. In preparing those financial statements, the trustees have:

- selected suitable accounting policies and applied them consistently;
- made judgements and estimates that are reasonable and prudent;
- followed applicable accounting standards, subject to any material departures disclosed and explained in the financial statements; and
- prepared the financial statements on the 'going concern' basis.

The trustees have maintained adequate accounting records, which disclose with reasonable accuracy at any time the financial position of the company, enabling them to ensure that the financial statements comply with the Companies Act 2006. They have safeguarded the assets of the company and taken reasonable steps for the prevention and detection of fraud and other irregularities.

### Statement of disclosure to auditors

(a) As far as the trustees are aware, there is no relevant audit information of which the company's auditors are unaware, and

(b) The trustees have taken all the steps that they ought to have taken in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

### Auditors

The auditors, Mazars LLP, have signified their willingness to continue in office. A resolution to re-appoint them as auditors will be proposed at the forthcoming annual general meeting.

The trustees have prepared this report in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small entities.

Approved and signed on behalf of the trustees by



.....  
Ms ME Schaafsma, Trustee and Treasurer

Date: 30 August 2013.

## THE COCHRANE COLLABORATION

### INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE COCHRANE COLLABORATION

We have audited the financial statements of The Cochrane Collaboration for the year ended 31 March 2013 which comprise the Statement of Financial Activities, the Consolidated Statement of Financial Activities, the Group (and Parent Charitable Company) Balance Sheets and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

#### **Respective responsibilities of trustees and auditor**

As explained more fully in the Trustees' Responsibilities Statement set out on page 7, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors. This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body for our audit work, for this report, or for the opinions we have formed.

#### **Scope of the audit of the financial statements**

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at [www.frc.org.uk/auditscopeukprivate](http://www.frc.org.uk/auditscopeukprivate).

#### **Opinion on the financial statements**

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 March 2013 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

#### **Opinion on the other matter prescribed by the Companies Act 2006**

In our opinion the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

#### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Act 2011 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit. ; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report.



Stephen Brown (Senior Statutory Auditor)  
for and on behalf of Mazars LLP  
Chartered Accountants and Statutory Auditor  
The Pinnacle  
160 Midsummer Boulevard  
Milton Keynes  
MK9 1FF  
11 December 2013

**THE COCHRANE COLLABORATION**

**STATEMENT OF FINANCIAL ACTIVITIES**

For the year ended 31 March 2013

Charity only (see over for group accounts)

	Note	Restricted	Designated	Unrestricted	2013	Restated 2012
		£	£	£	£	£
<b>INCOMING RESOURCES</b>						
<b>Incoming resources from generated funds</b>						
Voluntary Income	3	8,337	10	-	8,347	37,273
Investment Income	4	468	-	3,945,126	3,945,594	2,887,689
<b>Total Incoming Resources</b>		<b>8,805</b>	<b>10</b>	<b>3,945,126</b>	<b>3,953,941</b>	<b>2,924,962</b>
<b>RESOURCES EXPENDED</b>						
Costs of Generating Funds	7	-	-	599,839	599,839	372,978
Charitable Activities	8	81,521	9,914	1,582,701	1,674,136	1,759,938
Governance Costs	9	-	-	223,872	223,872	192,086
<b>Total Resources Expended</b>		<b>81,521</b>	<b>9,914</b>	<b>2,406,412</b>	<b>2,497,847</b>	<b>2,325,002</b>
<b>Net (Outgoing)/Incoming Resources Before Transfers</b>		<b>(72,716)</b>	<b>(9,904)</b>	<b>1,538,714</b>	<b>1,456,094</b>	<b>599,960</b>
<b>Fund Transfers</b>	16,17	<b>(2,174)</b>	<b>(5,202)</b>	<b>7,376</b>	<b>-</b>	<b>-</b>
<b>Net (Outgoing)/Incoming Resources</b>		<b>(74,890)</b>	<b>(15,106)</b>	<b>1,546,090</b>	<b>1,456,094</b>	<b>599,960</b>
<b>Reconciliation of funds</b>						
Total funds brought forward at 1 April		213,273	55,098	3,849,178	4,117,549	3,517,589
<b>TOTAL FUNDS CARRIED FORWARD AT 31 MARCH</b>	16,17	<b>138,383</b>	<b>39,992</b>	<b>5,395,268</b>	<b>5,573,643</b>	<b>4,117,549</b>

The statement of financial activities includes all gains and losses recognised in the year.

The charity's incoming resources and expended resources all relate to continuing operations.

The 2012 income has been restated to better reflect the split of income in the charity in line with the current year.

The funds carried forward at 31 March 2013 of £5,573,643 differ from the consolidated funds of £5,523,038 on page 10 due to the net reserves retained in the trading subsidiaries, Collaboration Trading Company Limited and Cochrane Innovations Limited.

The notes on pages 12 to 22 form part of these accounts.

THE COCHRANE COLLABORATION

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES

For the year ended 31 March 2013

	Note	Restricted	Designated	Unrestricted	Group 31 March 2013	Restated Group 31 March 2012
		£	£	£	£	£
<b>INCOMING RESOURCES</b>						
<b>Incoming resources from generated funds</b>						
Voluntary Income	3	8,337	10	-	8,347	37,273
Investment Income	4	468	-	41,789	42,257	36,071
<b>Incoming resources from charitable activities</b>	6	-	-	3,972,142	3,972,142	2,954,148
<b>Total Incoming Resources</b>		<u>8,805</u>	<u>10</u>	<u>4,013,931</u>	<u>4,022,746</u>	<u>3,027,492</u>
<b>RESOURCES EXPENDED</b>						
Costs of Generating Funds	7	-	-	599,839	599,839	372,978
Charitable Activities	8	81,521	9,914	1,582,701	1,674,136	1,759,938
Governance Costs	9	-	-	340,247	340,247	297,128
<b>Total Resources Expended</b>		<u>81,521</u>	<u>9,914</u>	<u>2,522,787</u>	<u>2,614,222</u>	<u>2,430,044</u>
<b>Net Incoming/(Outgoing) Resources before transfers</b>		(72,716)	(9,904)	1,491,144	1,408,524	597,448
<b>Fund Transfers</b>	16, 17	(2,174)	(5,202)	7,376	-	-
<b>Net Incoming/(Outgoing) Resources</b>		(74,890)	(15,106)	1,498,520	1,408,524	597,448
Fund balances brought forward at 1 April		<u>213,273</u>	<u>55,098</u>	<u>3,846,143</u>	<u>4,114,514</u>	<u>3,517,066</u>
<b>FUND BALANCES CARRIED FORWARD AT 31 MARCH</b>	16, 17	<u>138,383</u>	<u>39,992</u>	<u>5,344,663</u>	<u>5,523,038</u>	<u>4,114,514</u>

The statement of financial activities includes all gains and losses recognised in the year.

The group's incoming resources and expended resources all relate to continuing operations.

The 2012 income has been restated to better reflect the split of income in the charity in line with the current year.

The notes on pages 12 to 22 form part of these accounts.

THE COCHRANE COLLABORATION

BALANCE SHEETS  
As at 31 March 2013

COMPANY NO. 3044323

		Cochrane		Cochrane	
		Collaboration	Group	Collaboration	Group
	Note	31 March	31 March	31 March	31 March
		2013	2013	2012	2012
		£	£	£	£
<b>FIXED ASSETS</b>					
Fixtures, Fittings & Equipment	11	8,173	14,425	11,922	13,923
Investments	12	301,200	1,000	151,200	1,000
		<u>309,373</u>	<u>15,425</u>	<u>163,122</u>	<u>14,923</u>
<b>CURRENT ASSETS</b>					
Debtors	13	2,853,062	1,808,677	1,180,247	1,324,488
Cash at bank and in hand		2,758,309	5,466,392	3,029,462	3,564,035
		<u>5,611,371</u>	<u>7,275,069</u>	<u>4,209,709</u>	<u>4,888,523</u>
<b>CREDITORS - AMOUNTS FALLING DUE WITHIN ONE YEAR</b>	14	(347,101)	(817,456)	(255,282)	(788,932)
		<u>5,264,270</u>	<u>6,457,613</u>	<u>3,954,427</u>	<u>4,099,591</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>5,573,643</u>	<u>6,473,038</u>	<u>4,117,549</u>	<u>4,114,514</u>
<b>CREDITORS - AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR</b>	15	-	(950,000)	-	-
<b>NET ASSETS</b>		<u>5,573,643</u>	<u>5,523,038</u>	<u>4,117,549</u>	<u>4,114,514</u>
<b>INCOME FUNDS</b>					
Restricted funds	16	138,383	138,383	213,273	213,273
Unrestricted funds:					
Designated	17	39,992	39,992	55,098	55,098
Other unrestricted		5,395,268	5,344,663	3,849,178	3,846,143
	18	<u>5,573,643</u>	<u>5,523,038</u>	<u>4,117,549</u>	<u>4,114,514</u>

The notes on pages 12 to 22 form part of these accounts.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small entities.

Approved and authorised for issue by the trustees on 30 August 2013 and signed on their behalf by



Ms M E Schaafsma  
Trustee and Treasurer

# THE COCHRANE COLLABORATION

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

### 1. ACCOUNTING POLICIES

The financial statements have been prepared in accordance with applicable accounting standards and the Statement of Recommended Practice "Accounting for Charities" issued by the Charity Commission in 2005 with the approval of the Accounting Standards Board.

The charity's main accounting policies are as follows:

#### a) Accounting Convention

The financial statements are prepared under the historical cost convention (i.e. balances are recorded at the original cost and are not subsequently revalued).

#### b) Incoming Resources

Donations, legacies and gifts income is recognised on a receipts basis (i.e. when it is virtually certain that the income will be received) under Gift Aid from the subsidiary undertakings, Collaboration Trading Company Limited and Cochrane Innovations Limited, and is recognised on a receivable basis (i.e. when the income is earned).

Group incoming resources include royalties from the subscriptions to and sales of The Cochrane Library to Collaboration Trading Company Limited, which are recognised on a receivable basis (i.e. when the income is earned). In the consolidated Statement of Financial Activities (SOFA) this income has been included in incoming resources from charitable activities.

A sign on fee in relation to a new agreement signed in the year has been included in deferred income. The income will be recognised on a straight line basis over the life of the agreement.

Investment income, representing amounts received from subsidiary and bank interest earned, is recognised on a receivable basis (i.e. when the income is earned).

#### c) Resources Expended

Expenditure shown in the accounts includes accruals for goods and services rendered up to the financial period end.

Expended resources are classified between the relevant activity categories of resources expended as relevant to the nature of the expenditure incurred. All expenditure is considered to be directly chargeable to the relevant activity category apart from salary costs for COU staff which are apportioned evenly across activity categories.

#### d) Fixed Assets

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the costs less estimated residual value of each asset over its expected useful life as follows:

Plant and machinery	33% Straight Line Method
Fixtures, fittings and equipment	25% Straight Line Method

Fixed assets with an initial cost of under £100 are not capitalised.

#### e) Investments

Investments in subsidiary undertakings are included at cost.

Other investments are included at cost or deemed cost due to the non availability of reliable market values.

#### f) Basis of Consolidation

The income and expenditure and assets and liabilities of Collaboration Trading Company Limited and Cochrane Innovations Limited are consolidated within the results of The Cochrane Collaboration. All amounts in respect of group balances and transactions have been eliminated in arriving at the group figures.

Amounts disclosed in the accounts under the Trading Companies columns in the Notes to the Accounts are for information purposes only.

#### g) Funds Structure

The charity holds a number of funds which have been restricted for specific purposes by the donors. These are classified under "restricted funds". The charity holds funds which have been internally designed for specific purposes. These are classified under "designated funds".

# THE COCHRANE COLLABORATION

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

### h) Unrestricted Funds

Unrestricted funds represent revenue grants and donations and interest receivable etc, which can be applied to the objectives of the charity. Transfers out of unrestricted funds represent new designations made in the period and are detailed in note 16.

### i) Grant Expenditure

Grants payable are recognised in the year in which the offer is accepted by the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued expenditure.

### j) Foreign Exchange

Transactions denominated in foreign currencies are translated into sterling on the exchange rate ruling on the date of transaction.

### k) Operating Leases

Rentals payable under operating leases are charged on a straight line basis over the term of the lease.

### l) Financial Commitments

Approved grants are recognised as liabilities once approved by the trustees and communicated to the beneficiary.

### m) Liabilities

When an obligation exists that will probably lead to expended resources after the year end, a liability is recognised.

### n) Governance Costs

Expended resources are recognised as governance costs where they relate to the oversight of the charity.

## 2. SURPLUS FOR THE FINANCIAL YEAR

	Cochrane Collaboration 2013 £	Collaboration Trading Co. 2013 £	Cochrane Innovations 2013 £	Group 2013 £	Group 2012 £
The surplus is after charging:					
Auditors' remuneration - audit services	2,500	1,500	1,500	5,500	5,000
- non – audit	500	1,500	750	2,750	-

## 3. VOLUNTARY INCOME

	Restricted £	Designated £	Unrestricted £	Cochrane Collaboration 2013 £	Collaboration Trading Co. 2013 £	Cochrane Innovations 2013 £	Group 2013 £	Restated Group 2012 £
Donations	8,337	10	-	8,347	-	-	8,347	37,27
	8,337	10	-	8,347	-	-	8,347	37,27

The 2012 income has been restated to better reflect the split of income in the charity in line with the current year.

# THE COCHRANE COLLABORATION

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

### 4. INVESTMENT INCOME

	Restricted	Designated	Unrestricted	Cochrane Collaboration	Collaboration Trading Co.	Cochrane Innovations	Group	Group
	2013	2013	2013	2013	2013	2013	2013	2012
	£	£	£	£	£	£	£	£
Bank interest	468	-	28,953	29,421	12,762	74	42,257	36,071
	468	-	28,953	29,421	12,762	74	42,257	36,071

Investment income in the Charity SOFA of £3,945,594 (2011-12: £2,887,689) also includes monies receivable from Collaboration Trading Company Limited for donations made under Gift Aid.

### 5. TAXATION

The Cochrane Collaboration is a registered charity, and is therefore not liable to pay corporation tax on its charitable activities. The Collaboration Trading Company and Cochrane Innovations are not charities and are therefore subject to corporation tax on their activities. However, the net profit chargeable to corporation tax on their trading activities are considered as donations on an annual basis. On this basis, no provision has been made for corporation tax.

### 6. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES

	Cochrane Collaboration 2013	Collaboration Trading Co. 2013	Cochrane Innovations 2013	Group 2013	Group 2012
	£	£	£	£	£
<b>Unrestricted Funds</b>					
Royalties from subscriptions to and sales of The Cochrane Library and other income	-	3,908,306	-	3,908,306	2,878,398
Other income	-	-	63,836	63,836	75,750
	-	3,908,306	63,836	3,972,142	2,954,148

Donations made from Collaboration Trading Company Limited and Cochrane Innovations Limited to The Cochrane Collaboration under Gift Aid are included in the charity's income as Investment Income and are shown in note 4.

### 7. COSTS OF GENERATING FUNDS

	Restricted	Designated	Un- restricted	Cochrane Collaboration 2013	Collaboration Trading Co. 2013	Cochrane Innovations 2013	Group 2013	Group 2012
	£	£	£	£	£	£	£	£
Meeting expenses	-	-	195,035	195,035	-	-	195,035	34,688
Staff salaries (see note 10)	-	-	110,531	110,531	-	-	110,531	101,602
Editorial costs	-	-	294,273	294,273	-	-	294,273	236,708
	-	-	599,839	599,839	-	-	599,839	372,978



**THE COCHRANE COLLABORATION**

**NOTES TO THE FINANCIAL STATEMENTS**

For the year ended 31 March 2013

**8. COSTS OF ACTIVITIES IN FURTHERANCE OF CHARITABLE OBJECTIVES**

**Awards, Scholarships & Prizes**

	Restricted £	Designated £	Unrestricted £	Cochrane Collaboration 2013 TOTAL £	Collaboration Trading Co. 2013 Unrestricted £	Cochrane Innovations 2013 Unrestricted £	Group 2013 £	Group 2012 £
Anne Anderson Award	1,875	-	-	1,875	-	-	1,875	-
Thomas C Chalmers Award	631	-	-	631	-	-	631	637
Aubrey Sheiham Scholarship	5,686	-	-	5,686	-	-	5,686	6,269
Chris Silagy Prize	-	-	3,180	3,180	-	-	3,180	1,087
Bill Silverman Prize	622	-	-	622	-	-	622	643
Kenneth Warren Prize	3,825	-	-	3,825	-	-	3,825	2,369

**Total Awards, Scholarship & Prizes**

	12,639	-	3,180	15,819	-	-	15,819	11,005
--	--------	---	-------	--------	---	---	--------	--------

Vitamin A Project	-	-	-	-	-	-	-	9,974
HTA Influenza Project	3,274	-	-	3,274	-	-	3,274	-
NHS Updating Project	-	-	-	-	-	-	-	36,167
Evidence Aid	65,608	-	-	65,608	-	-	65,608	24,506
Direct/Running costs	-	-	70,647	70,647	-	-	70,647	52,526
Designated grants	-	9,914	61,200	71,114	-	-	71,114	107,657
Grants	-	-	187,176	187,176	-	-	187,176	323,525
IMS Support team	-	-	31,525	31,525	-	-	31,525	96,147
IMS development	-	-	320,085	320,085	-	-	320,085	330,548
Legal Fees	-	-	26,289	26,289	-	-	26,289	26,649
Meeting expenses	-	-	41,123	41,123	-	-	41,123	9,551
Staff salaries (see note 10)	-	-	563,799	563,799	-	-	563,799	584,918
Website development	-	-	277,677	277,677	-	-	277,677	146,765

	81,521	9,914	1,582,701	1,674,136	-	-	1,674,136	1,759,938
--	--------	-------	-----------	-----------	---	---	-----------	-----------

## THE COCHRANE COLLABORATION

### NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

#### 8. COSTS OF ACTIVITIES IN FURTHERANCE OF CHARITABLE OBJECTIVES (continued)

Items of negative expenditure, shown in parentheses, represent projects committed and provided in prior years where the actual costs were lower than originally provided. Overprovided amounts have been released to the Statement of Financial Activities in the year

Grants were made to the following projects:

	£
EUnetHTA	5,472
Cochrane Register of Studies	73,530
Cochrane Advocacy Initiative	263
Cochrane Global Initiative	(14,943)
Cochrane Marketing Initiative	28,695
Colloquium Manager development	7,554
Consumer Co-ordinator	7,221
Translation Working Group	144
Translation Strategy	354
Anniversary Celebrations	36,982
WHO Official Relations (Partner)	1,513
FPAP Budget	48,491
ECRAN	(8,100)
	187,176

#### 9. GOVERNANCE COSTS

	Cochrane Collaboration 2013 £	Collaboration Trading Co. 2013 £	Cochrane Innovations 2013 £	Group 2013 £	Group 2012 £
Advisory group costs	-	-	-	-	2,264
Audit and accountancy	3,000	3,000	2,250	8,250	25,505
Bank interest and charges	2,191	-	179	2,370	2,169
Insurance	240	197	390	827	6,533
Legal and professional	-	14,791	5,371	20,162	1,076
Meeting expenses	105,289	-	-	105,289	77,156
Printing, postage and stationery	-	9,081	206	9,287	5,975
Running costs	2,621	59,102	7,726	69,449	53,149
Staff salaries (see note 10)	110,531	-	14,082	124,613	121,914
Telephone	-	-	-	-	1,387
	223,872	86,171	30,204	340,247	297,128

All governance expenditure is from unrestricted funds.

**THE COCHRANE COLLABORATION**

**NOTES TO THE FINANCIAL STATEMENTS**

For the year ended 31 March 2013

**10. TOTAL STAFF COSTS**

	Cochrane Collaboration 2013 £	Collaboration Trading Co. 2013 £	Cochrane Innovations 2013 £	Group 2013 £	Group 2012 £
Wages and salaries	690,204	-	14,082	704,286	714,915
Social security costs	57,153	-	-	57,153	63,845
Pension costs	37,503	-	-	37,503	29,674
	<u>784,860</u>	<u>-</u>	<u>14,082</u>	<u>798,942</u>	<u>808,434</u>

Staff Costs have been apportioned between the headings in the Statement of Financial Activities in accordance with the accounting policy, as follows:

	Cochrane Collaboration 2013 £	Collaboration Trading Co. 2013 £	Cochrane Innovations 2013 £	Group 2013 £
Costs of Generating Funds	110,531	-	-	110,531
Costs in Furtherance of the Charity's Objects	563,799	-	-	563,799
Governance Costs	110,531	-	14,082	124,613
	<u>784,861</u>	<u>-</u>	<u>14,082</u>	<u>798,943</u>

	Cochrane Collaboration 2013	Collaboration Trading Co. 2013	Cochrane Innovations 2013	Group 2013	Group 2012
The average number of employees analysed by function was:					
Management	3	-	-	3	6
Finance	2	-	-	2	4
Administration	8	-	1	9	5
	<u>13</u>	<u>-</u>	<u>1</u>	<u>14</u>	<u>15</u>

3 employees received emoluments in excess of £60,000 during the year (2011 - 2012: 3).

**Trustees' remuneration and expenses**

The Trustees received no remuneration during the year, apart from reimbursement of direct expenses for attendance at Trustees' meetings in furtherance of their duties of £94,416 (2011 -2012: £57,415).

Professional indemnity insurance was purchased in the year for £5,413 (2011 - 2012: £5,915).

## THE COCHRANE COLLABORATION

### NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

#### 11. FIXED ASSETS

	Collaboration			Group		
	Fixtures & Fittings	Computer Equipment	Total	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£	£	£
<b>Cost</b>						
As at 1 April 2012	9,855	13,541	23,396	22,170	31,899	54,069
Additions	89	2,048	2,137	246	8,963	9,209
Disposals	-	-	-	(7,020)	(5,823)	(12,843)
As at 31 March 2013	<u>9,944</u>	<u>15,589</u>	<u>25,533</u>	<u>15,396</u>	<u>35,039</u>	<u>50,435</u>
<b>Depreciation</b>						
As at 1 April 2012	5,056	6,418	11,474	16,771	23,375	40,146
Charge for the year	2,348	3,538	5,886	2,622	6,085	8,707
Disposals	-	-	-	(7,020)	(5,823)	(12,843)
As at 31 March 2013	<u>7,404</u>	<u>9,956</u>	<u>17,360</u>	<u>12,373</u>	<u>23,637</u>	<u>36,010</u>
<b>Net Book Value</b>						
As at 31 March 2013	<u>2,540</u>	<u>5,633</u>	<u>8,173</u>	<u>3,023</u>	<u>11,402</u>	<u>14,425</u>
As at 31 March 2012	<u>4,799</u>	<u>7,123</u>	<u>11,922</u>	<u>5,399</u>	<u>8,524</u>	<u>13,923</u>

#### 12. FIXED ASSETS INVESTMENTS

	Cochrane Collaboration 2013	Group 2013	Cochrane Collaboration 2012	Group 2012
	£	£	£	£
Investment in Collaboration Trading Company Limited	100	-	100	-
Investment in Cochrane Innovations Limited	300,100	-	150,100	-
Other investments	1,000	1,000	1,000	1,000
	<u>301,200</u>	<u>1,000</u>	<u>151,200</u>	<u>1,000</u>

The investments represent a 100% shareholding in Collaboration Trading Company Limited and a 100% shareholding in Cochrane Innovations Limited (incorporated in England and Wales). All figures have been included in the consolidation.

Other investments represent the value of the oil painting of the Cochrane logo gifted by Sir Iain Chalmers.

**THE COCHRANE COLLABORATION**

**NOTES TO THE FINANCIAL STATEMENTS**

For the year ended 31 March 2013

**13. DEBTORS**

	Cochrane Collaboration 2013	Group 2013	Cochrane Collaboration 2012	Group 2012
	£	£	£	£
<b>DEBTORS DUE WITHIN ONE YEAR</b>				
Prepayments and accrued income	19,956	1,082,637	483,833	1,287,546
Amount due from subsidiary	2,828,716	-	672,464	-
Other debtors	4,390	4,390	1,506	1,506
Trade debtors	-	379	22,444	35,436
<b>DEBTORS DUE AFTER MORE THAN ONE YEAR</b>				
Trade debtors	-	400,000	-	-
Prepayments and accrued income	-	321,271	-	-
	<u>2,853,062</u>	<u>1,808,677</u>	<u>1,180,247</u>	<u>1,324,488</u>

**14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	Cochrane Collaboration 2013	Group 2013	Cochrane Collaboration 2012	Group 2012
	£	£	£	£
Trade creditors	137,082	150,507	95,743	99,777
Social security and other taxation	24,710	24,710	17,732	17,733
VAT creditors	-	349,113	-	134,387
Other creditors	23,557	23,557	-	-
Accruals and deferred income	161,752	269,569	141,807	537,035
	<u>347,101</u>	<u>817,456</u>	<u>255,282</u>	<u>788,932</u>

**15. CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR**

	Cochrane Collaboration 2013	Group 2013	Cochrane Collaboration 2012	Group 2012
	£	£	£	£
Accruals and deferred Income	-	950,000	-	-
	<u>-</u>	<u>950,000</u>	<u>-</u>	<u>-</u>

THE COCHRANE COLLABORATION

NOTES TO THE FINANCIAL STATEMENTS  
For the year ended 31 March 2013

16. RESTRICTED FUNDS

	Balance as at 1 April 2012	Incoming resources	Expenditure	Transfer between funds	Balance as at 31 March 2013
	£	£	£	£	£
Kenneth Warren Prize	15,189	-	(3,825)	-	11,364
Bill Silverman Prize	2,501	-	(622)	-	1,879
Thomas C Chalmers Award	3,147	-	(631)	-	2,516
Aubrey Sheiham Scholarship	51,341	468	(5,686)	-	46,123
Vitamin A Project	5,448	-	-	(5,448)	-
HTA Influenza Project	-	-	(3,274)	3,274	-
Evidence Aid	128,867	6,964	(65,608)	-	70,223
Anne Anderson Award	6,780	1,373	(1,875)	-	6,278
Charity and Group	213,273	8,805	(81,521)	(2,174)	138,383

The Kenneth Warren Prize was formed to fund the annual prize of the same name.

The Bill Silverman Prize was formed to fund the annual prize of the same name.

The Thomas C Chalmers Award was formed to fund the annual prize of the same name.

The Aubrey Sheiham Scholarship Fund is to provide one three-month scholarship each year, in order that individuals from developing countries can learn to prepare systematic reviews.

WHO Vitamin A project – A commission from the World Health Organization to update a number of Cochrane Reviews on Vitamin A Supplementation in specific population groups. This project has since finished and all remaining funds have been donated to the CEU as support for their on-going work. Therefore, a transfer has been made to unrestricted funds.

HTA Influenza project – A grant awarded by the NIHR as part of the HTA programme to support a review team evaluating the effects of neuraminidase inhibitors in influenza.

Evidence Aid – An initiative to improve access to information for people and organisations facing health and healthcare challenges arising in natural disasters and other large-scale health emergencies and crises.

The Anne Anderson Prize was formed to fund the annual prize of the same name.

The bracketed figures represent expenditure which is deducted from the fund balances.

THE COCHRANE COLLABORATION

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

17. DESIGNATED FUNDS

	Balance as at 1 April 2012	Transfers and new designations	Incoming Resources	Expenditure	Balance as at 31 March 2013
	£	£	£	£	£
Discretionary Fund	15,000	9,914	-	(9,914)	15,000
Prioritisation Fund	13,184	-	-	-	13,184
Opportunities Fund	15,106	(15,116)	10	-	-
Colloquium Fund	11,808	-	-	-	11,808
	55,098	(5,202)	10	(9,914)	39,992

The charity designates to the Discretionary Fund a maximum of £15,000 of its unrestricted funds annually in support of those Cochrane entities which require funding for their activities which are in line with the charity's mission. Each successful application is restricted to £5,000 (exclusive of any administration charges).

A transfer has been made from the unrestricted reserves to increase the balance back up to £15,000 at the year end following expenditure of £9,914 from the fund in the year.

Agreed payments for the projects funded by the fourth and final round of the Collaboration's Opportunities Fund began in the year 2010-11, with all invoices for older projects settled as final reports were received. The Steering Group had agreed at its meeting in Auckland, New Zealand, in March 2010, to discontinue the Opportunities Fund on completion of the fourth round, considering that it was not contributing sufficiently to achieving the Collaboration's strategic goals. Instead, core funds will be directed at programmes considered of key strategic importance, including *Cochrane Training* and *Cochrane Methods*. These initiatives will include budgets allocated by application to groups conducting research, development, training and advocacy projects in relevant subject areas.

The Colloquium Fund has been established for activities associated with the preparation, administration, oversight, management and reporting related to the organisation of Cochrane Colloquia.

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Charity	Restricted	Unrestricted	Total
	£	£	£
Fixed assets	-	309,373	309,373
Current assets	138,383	5,472,988	5,611,371
Current liabilities	-	(347,101)	(347,101)
	138,383	5,435,260	5,573,643

## THE COCHRANE COLLABORATION

### NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 March 2013

Group	Restricted £	Unrestricted £	Total £
Fixed assets	-	15,425	15,425
Current assets	138,383	7,136,686	7,275,069
Current liabilities	-	(817,456)	(817,456)
Non current liabilities	-	(950,000)	(950,000)
	138,383	5,384,655	5,523,038

### 19. FINANCIAL COMMITMENTS

#### Operating lease commitments

At 31 March 2013 the charitable company had annual commitments in respect of premises rental as follows:

	Charity and Group		Charity and Group	
	2013	2013	2012	2012
	Land and buildings £	Other £	Land and buildings £	Other £
In one year or less	34,040	-	-	-
Over one and less than two	-	-	-	1,485
Over two and less than five	-	1,485	31,203	-
Over five years	21,650	-	21,650	-
	55,690	1,485	52,853	1,485

#### Pension Commitments

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £37,503 (2011 - 2012: £29,674). Contributions totalling £8,660 (2011 - 2012: £498) were payable to the fund at the balance sheet date and are included in creditors.

### 20. RELATED PARTY TRANSACTIONS

The charitable company has taken advantage of the exemption in Financial Reporting Standard Number 8 from the requirements to disclose transactions with group companies in consolidated financial statements.